Literature DB >> 1346796

Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.

M J Robertson1, R J Soiffer, S F Wolf, T J Manley, C Donahue, D Young, S H Herrmann, J Ritz.   

Abstract

Natural killer cell stimulatory factor (NKSF) is a 70-kD heterodimeric cytokine that was initially isolated from conditioned medium of human B lymphoblastoid cell lines. The effects of recombinant NKSF on the function of human peripheral blood NK cells were examined. NKSF directly augmented the cytolytic activity of freshly isolated NK cells. Both CD56dim and CD56bright NK cells demonstrated enhanced cytotoxicity after brief exposure to NKSF. In contrast, highly purified T lymphocytes did not exhibit major histocompatibility complex-unrestricted cytotoxicity after short-term culture with NKSF. Like interleukin 2 (IL-2), NKSF augmented the lysis of NK-sensitive, NK-resistant, and antibody-coated targets. Both NKSF and IL-2 induced marked upregulation of several NK cell adhesion molecules known to participate in cytolysis, including CD2, CD11a, and CD54. However, NKSF activates NK cells through a pathway distinct from that of IL-2, since the presence of anti-IL-2 receptor (anti-IL-2R) antibodies or IL-4 did not inhibit the effects of NKSF. NKSF by itself induced very little proliferation of resting NK cells. NK cells preactivated in vitro with IL-2 demonstrated enhanced proliferation to NKSF, but the degree of proliferation was always inferior to that induced by IL-2 alone. Moreover, NKSF strongly inhibited IL-2-induced proliferation of either resting or preactivated NK cells. This inhibition was not the result of decreased IL-2R expression, because NKSF-activated NK cells expressed higher levels of both IL-2Rs p75 and p55. Furthermore, NKSF did not inhibit the proliferation of mitogen-activated T cells, indicating a selective effect on NK cell proliferation. Human NK cells expanded in vivo by prolonged continuous infusions of IL-2 remained fully responsive to NKSF. Picomolar concentrations of NKSF were as effective as nanomolar concentrations of IL-2 in augmenting the cytolytic activity of NK cells expanded in vivo by IL-2. NKSF may play an important role in the regulation of human NK cell function, and its possible use as a therapeutic cytokine deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346796      PMCID: PMC2119162          DOI: 10.1084/jem.175.3.779

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  36 in total

Review 1.  Biology and clinical relevance of human natural killer cells.

Authors:  M J Robertson; J Ritz
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

2.  Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor.

Authors:  D P Gearing; D Cosman
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

3.  Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones.

Authors:  J Ritz; T J Campen; R E Schmidt; H D Royer; T Hercend; R E Hussey; E L Reinherz
Journal:  Science       Date:  1985-06-28       Impact factor: 47.728

Review 4.  Interferons and their actions.

Authors:  S Pestka; J A Langer; K C Zoon; C E Samuel
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

5.  Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor).

Authors:  M K Gately; B B Desai; A G Wolitzky; P M Quinn; C M Dwyer; F J Podlaski; P C Familletti; F Sinigaglia; R Chizonnite; U Gubler
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

6.  Comparative studies of human FcRIII-positive and negative natural killer cells.

Authors:  A Nagler; L L Lanier; S Cwirla; J H Phillips
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

7.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

8.  Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.

Authors:  M A Caligiuri; C Murray; R J Soiffer; T R Klumpp; M Seiden; K Cochran; C Cameron; C Ish; L Buchanan; D Perillo
Journal:  J Clin Oncol       Date:  1991-12       Impact factor: 44.544

9.  Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers.

Authors:  S H Chan; B Perussia; J W Gupta; M Kobayashi; M Pospísil; H A Young; S F Wolf; D Young; S C Clark; G Trinchieri
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

10.  Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.

Authors:  M A Caligiuri; A Zmuidzinas; T J Manley; H Levine; K A Smith; J Ritz
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

View more
  75 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma.

Authors:  G G Steger; M F Gnant; M P Djavanmard; R M Mader; R Jakesz; W Pierce; J B deKernion; R Figlin; A Belldegrun
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Continuous stress disrupts immunostimulatory effects of IL-12.

Authors:  Ben Levi; Marganit Benish; Yael Goldfarb; Liat Sorski; Rivka Melamed; Ella Rosenne; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2011-01-28       Impact factor: 7.217

4.  Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression.

Authors:  Jianguo Liu; Shanjin Cao; Sunjung Kim; Elaine Y Chung; Yoichiro Homma; Xiuqin Guan; Violeta Jimenez; Xiaojing Ma
Journal:  Curr Immunol Rev       Date:  2005-06

5.  CD27/CD70 interaction directly induces natural killer cell killing activity.

Authors:  F C Yang; K Agematsu; T Nakazawa; T Mori; S Ito; T Kobata; C Morimoto; A Komiyama
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

6.  IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro.

Authors:  N Bhardwaj; R A Seder; A Reddy; M V Feldman
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

7.  Inhibition of cancer cell motility and invasion by interleukin-12.

Authors:  S Hiscox; M B Hallett; M C Puntis; W G Jiang
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

8.  Cerebral expression of interleukin-12 induces neurological disease via differential pathways and recruits antigen-specific T cells in virus-infected mice.

Authors:  Markus Hofer; Jürgen Hausmann; Peter Staeheli; Axel Pagenstecher
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

9.  Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells.

Authors:  A Jewett; B Bonavida
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

10.  Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection.

Authors:  S J Lin; R L Roberts; B J Ank; Q H Nguyen; E K Thomas; E R Stiehm
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.